Engineers Gate Manager LP Makes New Investment in Solventum Corporation $SOLV

Key Points

• Engineers Gate Manager LP acquired 24,383 Solventum shares worth approximately $1.88 million during the second quarter, joining several other institutional investors that recently initiated or expanded positions.
• Solventum reported quarterly adjusted earnings of $2.55 per share, beating estimates of $1.91, while revenue rose 2.2% year over year to $2.21 billion. The company issued fiscal 2026 EPS guidance of $7.10 to $7.20.
• Analyst sentiment is broadly positive, with eight Buy ratings, three Holds and one Sell; the stock carries a “Moderate Buy” consensus rating and an average price target of $92.80.

Engineers Gate Manager LP acquired a new stake in Solventum Corporation (NYSE:SOLV - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 24,383 shares of the company's stock, valued at approximately $1,881,000.

A number of other institutional investors also recently modified their holdings of the company. Independent Franchise Partners LLP raised its holdings in Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in shares of Solventum in the 2nd quarter worth about $150,066,000. Norges Bank bought a new position in Solventum in the 4th quarter valued at about $147,467,000. Diamond Hill Capital Management Inc. boosted its stake in Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company's stock valued at $167,119,000 after purchasing an additional 1,272,921 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Solventum during the 2nd quarter worth approximately $61,460,000.

Solventum Stock Performance

Shares of SOLV stock opened at $90.06 on Wednesday. The firm has a market cap of $15.33 billion, a price-to-earnings ratio of 11.01, a P/E/G ratio of 1.40 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $94.16. The firm's 50-day simple moving average is $85.66 and its two-hundred day simple moving average is $76.80.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company's revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts forecast that Solventum Corporation will post 7.22 earnings per share for the current year.

Wall Street Analyst Weigh In

SOLV has been the topic of several analyst reports. Wall Street Zen raised Solventum from a "hold" rating to a "buy" rating in a research report on Saturday. Piper Sandler lifted their price objective on shares of Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. KeyCorp raised their price target on shares of Solventum from $93.00 to $102.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Finally, Stifel Nicolaus upped their price objective on shares of Solventum from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $92.80.

Solventum Company Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.